期刊文献+

95例耐多药结核菌株rpoB基因突变的分子特征 被引量:6

Molecular characteristics of rpoB gene of 95 multidrug-resistant Mycobacterium tuberculosis isolates
下载PDF
导出
摘要 目的:探讨广东地区MDR-TB菌株rpoB基因突变的分子特征。方法:对95例MDR-TB菌株rpoB基因453-564位密码子片段进行PCR-直接测序。结果:95例MDR-TB菌株rpoB基因突变率91.58%。86例为点突变,1例插入突变,未发现缺失。常见位点为531(63.22%)、526(20.69%)、516(9.20%)。其中:单位点突变69例(80.23%),双位点突变16例(18.60%),三位点突变1例(1.17%)。511位点突变常同时伴有其他位点突变(57.14%)。结论:主要突变位点与国内外报道基本相同,但各位点所占比例具有地域差异;联合突变率较高,占19.54%。512位点插入(AGGAGC)突变可能为新突变类型。 Objective To explore the molecular characteristics of rpoB gene of multidrug-resistant Mycobacterium tuberculosis(MDR-TB) isolates in Guangdong.Methods The codon from 453 to 564 in rpoB gene of 95 MDR-TB isolates was sequenced by PCR.Results The mutation rate of rpoB gene of 95 MDR-TB isolates was 91.58%,86 strains were point mutations,one strain was insertion mutation,there wasn't deletion mutation found.The most frequent mutations were in codon 531(63.22%),526(20.69%),and 516(9.20%).Among the mutation strains,69 were single-site mutation(80.23%),16 were double-site mutations(18.60%),1 was tri-site mutation(1.17%).About 57.14% of 511 site mutations were accompanied by other site mutations.Conclusions The major mutation sites of MDR-TB in Guangdong were similar to the results of domestic and international reports,but the proportions of each mutation form had regional differences.High combinative mutation rate(19.54%) and a new insertion form(512,AGGAGC) were found in this study.
出处 《实用医学杂志》 CAS 北大核心 2012年第14期2333-2335,共3页 The Journal of Practical Medicine
基金 广州市医药卫生科技项目重点项目(编号:2009-Zdi-22) 广州市医药卫生科技项目重大项目(编号:2009-ZDa-03) 国家“十一五”传染病防治重大科技专项(编号:2008ZX10003-007)
关键词 耐多药结核菌 RPOB基因 突变 Multidrug-resitance Mycobacterium tuberculosis RpoB gene Mutation
  • 相关文献

参考文献14

二级参考文献52

共引文献79

同被引文献100

  • 1王海英,徐勇,邓云峰,潘晞,Edward Graviss,马欣,刘志敏.山东省耐利福平结核分枝杆菌rpoB基因突变的研究[J].中国防痨杂志,2005,27(5):289-292. 被引量:6
  • 2中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007-2008年).北京:人民卫生出版社,2010:4.
  • 3Bloom BR, Murray CJ, Tuberculosis : commentary on areemergent killer [J]. Science, 1992,257(5073) : 1055-1064.
  • 4Guo JH, Xiang WL, Zhao QR, et al. Molecular Characterizationof Drug-Resistant Mycobacterium tuberculosis Isolates fromSichuan Province in China [J]. Jpn J Infect Dis, 2008,61 (4);264-268.
  • 5Doustdar F, Khosravi AD, Famia P, et al. Molecular analysis ofisoniazid resistance in different genotypes of Mycobacteriumtuberculosis isolates from iran [J]. Microb Drug Resist, 2008,4(14): 273-279.
  • 6Williams DL, Waguespack C, Eisenach K, et al. Characteriza tion of rifampin-resistance in pathogenic mycobacteria. Anti- microb Agents Chemother, 1994, 38(10) : 2380-2386.
  • 7Chaves F, Alonso Sanz M, Rebollo MJ, et al. rpoB mutations as an epidemiologic marker in rifampin-resistant Mycobacterium tuberulosis. Int J Tuberc Lung Dis, 2000, 4(8): 765 -770.
  • 8Williams DL, Spring L, Collins L, et al. Contribution of rpoB mutations to development of rifamyein erosresistance in My- cobacterium tuberculosis. Antimierob Agents Chemother, 1998, 42(7) : 1853-1857.
  • 9Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet, 2001, 40(5) :327-341.
  • 10Leonard t3, Coronel J, Siedner M, et al. Inter- and intrassay reproducibility of microplate Alamar blue assay results for iso niazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tube'culosis. J Clin Microbiol, 2008, 46(10): 3526-3529.

引证文献6

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部